Innovating Works

P95

Desconocido
VITAL: Vaccines and Infectious Diseases in the Ageing PopuLation P95 CVBA participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VI...
2018-12-10 - 2024-12-31 | Financiado
DRIVE: Development of Robust and Innovative Vaccine Effectiveness P95 CVBA participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the...
2017-08-08 - 2022-06-30 | Financiado
ADVANCE: Accelerated Development of Vaccine benefit-risk Collaboration in Europe P95 CVBA tramitó un FP6: Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
2013-10-01 - 2019-03-31 | Financiado
ADVANCE: Accelerated Development of Vaccine benefit risk Collaboration in Europe P95 CVBA tramitó un FP7: Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.